Discussion about this post

User's avatar
Neural Foundry's avatar

With all the dramatic shifts in health policy priorities documented here - from vaccine schedules to dietary guidelines - I'm concerned about what this means for rare disease research funding. These patients often rely on consistent NIH funding and regulatory stability for treatment development. When attention shifts to political battles over mainstream health programs, orphan drug research and rare disease initiatives risk getting deprioritized. The conflicts of interest you've highlighted with the new dietary panel make me wonder: who's advocating for the 10% of Americans with rare diseases when policy decisions are being made without consulting career experts?

No posts

Ready for more?